AstraZeneca scores again: Calquence approved for CLL as BTK race heats up
Six months after first boasting about Phase III data, AstraZeneca has earned expanded FDA approval for its BTK inhibitor Calquence. The drug will now be used to treat one of the most common adult blood cancers, chronic lymphocytic leukemia (CLL).
In the spring, the European giant called its shot early, pointing toward regulatory submissions as interim trial data came out. They said in May the drug had aced a Phase III trial as a second-line CLL treatment. Then in June, they announced high progression-free survival from patients in a trial of patients who received Calquence as a frontline therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
